PDF herunterladen
Horm Metab Res 2013; 45(01): 1-8
DOI: 10.1055/s-0032-1321874
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Thiazolidinediones (TZDs) Affect Osteoblast Viability and Biomarkers Independently of the TZD Effects on Aromatase

A. Seth
1   The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York, USA
,
V. Sy
1   The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York, USA
,
A. Pareek
1   The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York, USA
,
P. Suwandhi
1   The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York, USA
,
Z. Rosenwaks
2   Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine and Infertility, Weill Medical College of Cornell University New York, New York, USA
,
L. Poretsky
1   The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York, USA
,
D. Seto-Young
1   The Friedman Diabetes Institute, Division of Endocrinology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 16. März 2012

accepted 04. Juli 2012

Publikationsdatum:
09. August 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Thiazolidinediones (TZDs) are insulin sensitizers used for treatment of diabetes. We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC). Multiple clinical trials demonstrated that TZDs increase the risk of fractures in postmenopausal women with type 2 diabetes. We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism. Mouse osteoblasts were cultured with and without HGC, and incubated in a medium with or without testosterone, pioglitazone or rosiglitazone. Cell growth, oleic acid uptake, alkaline phosphatase activity, and osteocalcin production were measured. TZDs inhibited estradiol production by up to 84% in HGC/mouse osteoblast co-cultures. TZDs induced mouse osteoblast death and increased oleic acid uptake. TZDs also inhibited alkaline phosphatase activity (58–75%, p<0.046) and osteocalcin production (52–75%, p<0.031). For all the parameters, there were no significant differences between the osteoblast cultures alone and the HCG/osteoblast co-cultures. TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase.

Key words

osteoblast - oral antidiabetic drugs - bone homeostasis
 

  • References

  • 1 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ). J Biol Chem 1995; 270: 12953-12956
    CrossrefPubMedGoogle Scholar
  • 2 Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi A. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999; 46: 795-801
    CrossrefPubMedGoogle Scholar
  • 3 Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G. Diabetes Outcome Progression Trial (ADOPT) Study Group . Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 2008; 31: 845-851
    CrossrefPubMedGoogle Scholar
  • 4 Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92: 1305-1310
    CrossrefPubMedGoogle Scholar
  • 5 Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Basal Tutuncu N, Guvener Demiraq N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007; 92: 3523-3530
    CrossrefPubMedGoogle Scholar
  • 6 Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE. ADOPT Study Group . Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 134-142
    CrossrefPubMedGoogle Scholar
  • 7 Jung JY, Yoo CI, Kim HT, Kwon CH, Park JY, Kim YK. Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblast cell death. Toxicology 2007; 234: 73-82
    CrossrefPubMedGoogle Scholar
  • 8 Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implication for osteopenic disorders. J Bone Miner Res 1998; 13: 371-382
    CrossrefPubMedGoogle Scholar
  • 9 Johnson TE, Vogel R, Rutledge SJ, Rodan G, Schmidt A. Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 1999; 140: 3245-3254
    CrossrefPubMedGoogle Scholar
  • 10 Benvenuti S, Cellai I, Lluciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, Peri A, Serio M. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007; 30: 26-30
    PubMedGoogle Scholar
  • 11 Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005; 90: 6099-6105
    CrossrefPubMedGoogle Scholar
  • 12 Seto-Young D, Avtanski D, Parikh G, Suwandhi P, Strizhevsky M, Araki T, Rosenwaks Z, Poretsky L. Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. Horm Metab Res 2011; 43: 250-256
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 13 Araki T, Varadinova M, Goldman M, Rosenwaks Z, Poretsky L, Seto-Young D. Rosiglitazone and pioglitazone alter aromatase kinetic properties in human granulosa cells. PPAR Res 2011; 2011: 926438
    PubMedGoogle Scholar
  • 14 Kilbreath S, Refshauge KM, Beith J, Ward L, Sawkins K, Paterson R, Clifton-Bligh P, Sambrook PN, Simpson JM, Nery L. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of randomized controlled trial. Contemp Clin Trials 2011; 32: 704-709
    CrossrefPubMedGoogle Scholar
  • 15 Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85
    CrossrefPubMedGoogle Scholar
  • 16 Perry CG, Petrie JR. Insulin-sensitizing agents: beyond thiazolidinediones. Expert Opin Emerg Drugs 2002; 7: 165-174
    CrossrefPubMedGoogle Scholar
  • 17 Buckingham RE. Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol Res 2005; 33: 167-170
    CrossrefPubMedGoogle Scholar
  • 18 Reynolds K, Goldberg RB. Thiazolidinediones: Beyond glycemic control. Treat Endocrinol 2007; 5: 25-36
    PubMedGoogle Scholar
  • 19 Tarcin O, Bajaj M, Akalin S. Insulin resistance, adipocyte biology, and thiazolidinediones. Metab Syndr Rel Disord 2007; 5: 103-115
    PubMedGoogle Scholar
  • 20 Simó R, Rodriguez A, Caveda E. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Current Drug Safety 2010; 5: 234-244
    CrossrefPubMedGoogle Scholar
  • 21 Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O’Keefe M, Ghazzi MN. PCOS/Troglitazone Study Group . Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632
    CrossrefPubMedGoogle Scholar
  • 22 Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-566
    CrossrefPubMedGoogle Scholar
  • 23 Guido M, Romaualdi D, Suriano R, Giuliani M, Costantini B, Apa R, Lanzone A. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 2004; 19: 534-539
    CrossrefPubMedGoogle Scholar
  • 24 Brettenthaler N, DeGeyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone treatment on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835-3840
    CrossrefPubMedGoogle Scholar
  • 25 Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60-65
    CrossrefPubMedGoogle Scholar
  • 26 Froment P, Touraine P. Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR Res 2006; 2006: 73986
    PubMedGoogle Scholar
  • 27 Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and formation. Endocrinology 2005; 146: 1226-1235
    CrossrefPubMedGoogle Scholar
  • 28 Hasegawa T, Oizumi K, Yoshiko Y, Tanne K, Maeda N, Aubin JE. The PPAR-γ-selective BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. BMC Dev Biol 2008; 71: 1-12
    PubMedGoogle Scholar
  • 29 Zhang C. Transcription regulation of bone formation by the osteoblast-specific transcription factor Osx. J Orthop Surg Res 2010; 5: 1-37
    CrossrefPubMedGoogle Scholar
  • 30 Meury T, Akhouayri O, Jafarov T, Mandic V, St-Arnaud R. Nuclear αNAC influences bone matrix mineralization and osteoblast maturation in vivo. Mol Cell Biol 2010; 30: 43-53
    CrossrefPubMedGoogle Scholar
  • 31 Watanabe M, Ohno S, Nakajin S. Forskolin and dexamethasone synergistically induce aromatase (CYP19) expression in the human osteoblastic cell line SV-HFO. Eur J Endocrinol 2005; 152: 619-624
    CrossrefPubMedGoogle Scholar
  • 32 Shozu M, Zhao Y, Simpson ER. TGF-beta1 stimulates expression of the aromatase (CYP19) gene in human osteoblast-like cells and THP-1 cells. Mol Cell Endocrinol 2000; 160: 123-133
    CrossrefPubMedGoogle Scholar
  • 33 Ali AT, Penny CB, Paiker JE, van Niekerk C, Smit A, Ferris WF, Crowther NJ. Alkaline phosphatase is involved in the control of adipogenesis in the murine pre-adipocyte cell line, 3T3-L1. Clin Chim Acta 2005; 345: 101-109
    PubMedGoogle Scholar